Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-07-053283
Filing Date
2007-03-13
Accepted
2007-03-13 14:13:16
Documents
10
Period of Report
2006-12-31

Document Format Files

Seq Description Document Type Size
1 ANNUAL REPORT d10k.htm 10-K 874783
2 1995 STOCK OPTION PLAN dex106.htm EX-10.6 43899
3 AMENDMENT TO CONSULTING AGREEMENT dex1042.htm EX-10.42 7191
4 DIRECTOR COMPENSENTATION PROGRAM SUMMARY dex1043.htm EX-10.43 11823
5 CONSENT OF GRANT THORNTON LLP dex231.htm EX-23.1 1715
6 CERTIFICATION OF CHIEF EXECUTIVE OFFICER dex311.htm EX-31.1 9468
7 CERTIFICATION OF CHIEF FINANCIAL OFFICER dex312.htm EX-31.2 9545
8 CERTIFICATION OF CHIEF EXECUTIVE OFFICER dex321.htm EX-32.1 3363
9 CERTIFICATION OF CHIEF FINANCIAL OFFICER dex322.htm EX-32.2 3453
10 GRAPHIC g54559g47j65.jpg GRAPHIC 40526
  Complete submission text file 0001193125-07-053283.txt   1022935
Mailing Address 3625 132ND AVENUE SE SUITE 400 BELLEVUE WA 98006
Business Address 3625 132ND AVENUE SE SUITE 400 BELLEVUE WA 98006 4253730171
SCOLR Pharma, Inc. (Filer) CIK: 0000934936 (see all company filings)

EIN.: 911689591 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-31982 | Film No.: 07690163
SIC: 2835 In Vitro & In Vivo Diagnostic Substances